- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06040541
Study of RMC-9805 in Participants With KRASG12D-Mutant Solid Tumors
January 31, 2024 updated by: Revolution Medicines, Inc.
Phase 1/1b, Multicenter, Open-Label, Study of RMC 9805 in Participants With Advanced KRASG12D-Mutant Solid Tumors
This study is to evaluate the safety and tolerability of RMC-9805 in adults with KRAS G12D-mutant solid tumors.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
This is an open-label, multicenter, Phase 1/1b study of RMC-9805, monotherapy, selective and orally bioavailable KRAS G12D(ON) inhibitor, in subjects with KRASG12D-mutant solid tumors to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary clinical activity.
The study consists of two parts: Part 1- Dose-Exploration and Part 2- Dose-Expansion.
Study Type
Interventional
Enrollment (Estimated)
290
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Revolution Medicines, Inc.
- Phone Number: (650) 779-2300
- Email: CT-inquiries@RevMed.com
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Recruiting
- Massachusetts General Hospital
-
-
North Carolina
-
Huntersville, North Carolina, United States, 28078
- Recruiting
- Carolina BioOncology Institute
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
- Recruiting
- The Christ Hospital
-
-
Texas
-
Dallas, Texas, United States, 75230
- Recruiting
- Mary Crowley Cancer Research
-
Houston, Texas, United States, 77030
- Recruiting
- University of Texas, MD Anderson Cancer Center
-
San Antonio, Texas, United States, 78229
- Recruiting
- START
-
-
Virginia
-
Fairfax, Virginia, United States, 22031
- Recruiting
- Next Oncology Virginia
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Pathologically documented, locally advanced or metastatic solid tumor malignancy with KRASG12D-mutations identified through deoxyribonucleic acid (DNA) sequencing or polymerase chain reaction (PCR) test
- Received and progressed or been intolerant to prior standard therapy (including targeted therapy) appropriate for tumor type and stage
- ECOG performance status 0 or 1
- Adequate organ function
Exclusion Criteria:
- Primary central nervous system (CNS) tumors
- Known or suspected leptomeningeal or active brain metastases or spinal cord compression
- Known or suspected impairment of gastrointestinal function that may prohibit ability to swallow or absorb an oral medication
- Participant was previously treated with an investigational KRASG12D inhibitor or had prior therapy with any direct RAS-targeted therapy (eg, degraders and inhibitors)
Other inclusion/exclusion criteria may apply.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: RMC-9805
Dose exploration and dose expansion
|
Oral Tablets
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse events
Time Frame: Up to 3 years
|
Incidence and severity of treatment-emergent Adverse Events (AEs) and serious AEs and clinically significant changes in laboratory values, ECGs, and vital signs
|
Up to 3 years
|
Dose Limiting Toxicities
Time Frame: 21 days
|
Number of participants with Dose Limiting Toxicities (DLTs)
|
21 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Observed Blood Concentration (Cmax) of RMC-9805
Time Frame: up to 21 weeks
|
Cmax
|
up to 21 weeks
|
Time to Reach Maximum Blood Concentration (Tmax) of RMC-9805
Time Frame: up to 21 weeks
|
Tmax
|
up to 21 weeks
|
Area Under Blood Concentration Time Curve (AUC) of RMC-9805
Time Frame: up to 21 weeks
|
AUC
|
up to 21 weeks
|
Ratio of accumulation of RMC-9805 from a single dose to steady state with repeated dosing
Time Frame: up to 21 weeks
|
accumulation ratio of RMC-9805
|
up to 21 weeks
|
Elimination Half-Life (t1/2) of RMC-9805
Time Frame: up to 21 weeks
|
t1/2
|
up to 21 weeks
|
Overall Response Rate (ORR)
Time Frame: up to 3 years
|
Assess per RECIST v1.1
|
up to 3 years
|
Duration of Response (DOR)
Time Frame: up to 3 years
|
Assess per RECIST v1.1
|
up to 3 years
|
Disease Control Rate (DCR)
Time Frame: up to 3 years
|
Assess per RECIST v1.1
|
up to 3 years
|
Time to Response (TTR)
Time Frame: up to 3 years
|
Assess per RECIST v1.1
|
up to 3 years
|
Progression-Free Survival (PFS)
Time Frame: up to 3 years
|
Assess per RECIST v1.1
|
up to 3 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Revolution Medicines, Inc., Revolution Medicines, Inc.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 7, 2023
Primary Completion (Estimated)
August 30, 2025
Study Completion (Estimated)
July 31, 2026
Study Registration Dates
First Submitted
August 31, 2023
First Submitted That Met QC Criteria
September 8, 2023
First Posted (Actual)
September 15, 2023
Study Record Updates
Last Update Posted (Actual)
February 1, 2024
Last Update Submitted That Met QC Criteria
January 31, 2024
Last Verified
September 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Respiratory Tract Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Colorectal Neoplasms
- Adenocarcinoma
Other Study ID Numbers
- RMC-9805-001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Solid Tumors
-
AmgenCompletedCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced MalignancyUnited States, Australia
-
NantCell, Inc.CompletedQUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid TumorsCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced Malignancy
-
Incyte CorporationRecruitingA Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsAdvanced Solid Tumors | Solid Tumors | Metastatic Solid TumorsUnited States, Spain, United Kingdom, France, Italy, Denmark, Switzerland
-
Hoffmann-La RocheCompletedSolid Tumors, Advanced Solid TumorsUnited States
-
Esperance Pharmaceuticals IncCompletedAdvanced Solid Tumors | Solid TumorsUnited States
-
Genentech, Inc.RecruitingAdvanced Solid Tumors | Metastatic Solid TumorsCanada, Korea, Republic of, United States, Brazil, Australia, Argentina, Spain, New Zealand, Poland
-
Millennium Pharmaceuticals, Inc.CompletedAdvanced Solid Tumors, Neoplasms, Advanced SolidHungary
-
Incyte Biosciences Japan GKCompletedAdvanced Solid Tumors | Metastatic Solid TumorsJapan
-
Memorial Sloan Kettering Cancer CenterKyowa Hakko Kirin Pharma, Inc.CompletedAdvanced Solid Tumors | Metastatic Solid TumorsUnited States
-
Bristol-Myers SquibbCompletedAdvanced Solid Tumors | Metastatic Solid TumorsKorea, Republic of, Canada, Australia
Clinical Trials on RMC-9805
-
Dong-A ST Co., Ltd.Completed
-
Revolution Medicines, Inc.Active, not recruitingSolid TumorsUnited States
-
Revolution Medicines, Inc.SanofiActive, not recruitingSolid TumorsUnited States
-
Nicholas ButowskiNational Cancer Institute (NCI); Revolution Medicines, Inc.RecruitingGlioblastoma | Recurrent GlioblastomaUnited States
-
Chestnut Health SystemsRecruitingOpioid-use DisorderUnited States
-
The Netherlands Cancer InstituteLustgarten FoundationRecruitingColorectal Cancer | Pancreatic Cancer | Non-small Cell Lung Cancer | KRAS Mutation-Related TumorsNetherlands
-
Revolution Medicines, Inc.Sanofi; AmgenActive, not recruitingNon-Small Cell Lung CancerUnited States, Korea, Republic of, Canada, Taiwan, Spain, United Kingdom, Italy, Australia, France, Germany
-
University Hospital TuebingenJohannes Gutenberg University Mainz; Heinen und Löwenstein GmbH & Co. KGCompletedInfant Respiratory Distress Syndrome | Ventilator Lung; NewbornGermany
-
Revolution Medicines, Inc.RecruitingAdvanced Solid Tumor | Pancreatic Ductal Adenocarcinoma | Non-Small Cell Lung Cancer (NSCLC) | Colorectal Cancer (CRC)United States, Italy, Spain, Malaysia, Korea, Republic of, France, Australia, Thailand, Taiwan, Poland, Singapore, Czechia, Serbia
-
Revolution Medicines, Inc.RecruitingAdvanced Solid Tumors | Non-small Cell Lung Cancer (NSCLC) | Pancreatic Ductal Adenocarcinoma (PDAC) | Colorectal Cancer (CRC)United States